<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01153620</url>
  </required_header>
  <id_info>
    <org_study_id>OPM-CIC-G-H-0901</org_study_id>
    <nct_id>NCT01153620</nct_id>
  </id_info>
  <brief_title>The Antiseptic Efficacy and Tolerability of Lavasept® 0.04% on Acute Traumatic Wounds</brief_title>
  <acronym>Lavasept 2</acronym>
  <official_title>Randomized, Double-blind, Controlled Clinical Trial on the Antiseptic Efficacy and Tolerability of Lavasept® 0.04% on Acute Traumatic Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Ltd. Centre of Excellence Infection Control</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Ltd. Centre of Excellence Infection Control</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the antiseptic efficacy of Lavasept 0.04%
      when used as an antiseptic agent and to compare these with Ringers' solution in patients with
      acute traumatic wounds.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction (log10) in Colony Forming Units</measure>
    <time_frame>60 minutes</time_frame>
    <description>Comparison of the log10 reduction in CFU after 60 minutes of treatment application.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Tolerability: Pruritis Burning</measure>
    <time_frame>60 minutes</time_frame>
    <description>Local tolerability after 60 minutes of treatment application.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in CFU</measure>
    <time_frame>15 minutes, 30 minutes and 60 minutes</time_frame>
    <description>Comparison of the percentage reduction in CFU after 15, 30 and 60 minutes of treatment application</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the Percentage of Patients With Target Wounds &lt;50 CFU</measure>
    <time_frame>60 minutes</time_frame>
    <description>Comparison of the percentage of patients with target wounds &lt;50 CFU after 60 minutes of treatment application</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Wounds</condition>
  <arm_group>
    <arm_group_label>Ringer's Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lavasept 0.04%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lavasept 0.04%</intervention_name>
    <description>Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.
Dosage Lavasept® 0.04% 50 ml 50ml or as much needed to completely saturate the compress.
Treatment Duration 60 minutes</description>
    <arm_group_label>Lavasept 0.04%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ringer's Solution</intervention_name>
    <description>Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.
Dosage Ringers' solution 50ml or as much needed to completely saturate the compress. Treatment Duration 60 minutes</description>
    <arm_group_label>Ringer's Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute traumatic cut, crush, abrasion, bite or stab wounds Provision of
             voluntary consent to participate in the study, following a full explanation of the
             nature and purpose of the study, by signing the informed consent form approved by the
             Institutional Ethics Committee (IEC) prior to all evaluations

          -  Wounds that are a minimum of approximately 4 cm2 in size

          -  Ability to read and understand the German patient information sheet and informed
             consent form

        Exclusion Criteria:

          -  &lt; 18 years of age

          -  Pregnancy

          -  Immunosuppression

          -  Wounds caused by a burn

          -  Wounds that require treatment of hyaline cartilage, the central nervous system,
             peritoneum, meningae, inner / middle ear or inner eye

          -  Simultaneous participation in another clinical trial

          -  Wounds that require immediate surgical or medical treatment as well patients who are
             critically ill

          -  Patient with a known allergy to the active agent or any of the excipients

          -  Wounds that are &gt;3 cm in depth

          -  Wounds that have not received medical treatment for ≥6 hours

          -  Heavily bleeding wounds

          -  Open fractures, joints or tendons

          -  Wounds of the face
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Peter Simmen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2010</study_first_submitted>
  <study_first_submitted_qc>June 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2010</study_first_posted>
  <results_first_submitted>October 21, 2011</results_first_submitted>
  <results_first_submitted_qc>October 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 29, 2011</results_first_posted>
  <last_update_submitted>April 5, 2012</last_update_submitted>
  <last_update_submitted_qc>April 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute traumatic wounds</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Anti-Infective Agents, Local</mesh_term>
    <mesh_term>Polihexanide</mesh_term>
    <mesh_term>Biguanides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Location: Emergency roon in University Hospital</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ringer's Solution</title>
        </group>
        <group group_id="P2">
          <title>Lavasept 0.04%</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30">30 patients (31 wounds)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30">30 patients (31 wounds)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ringer's Solution</title>
        </group>
        <group group_id="B2">
          <title>Lavasept 0.04%</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.63" spread="24.487"/>
                    <measurement group_id="B2" value="47.68" spread="23.019"/>
                    <measurement group_id="B3" value="47.66" spread="23.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction (log10) in Colony Forming Units</title>
        <description>Comparison of the log10 reduction in CFU after 60 minutes of treatment application.</description>
        <time_frame>60 minutes</time_frame>
        <population>ITT population: comprising all wounds having received the study treatment for any duration (n=61).</population>
        <group_list>
          <group group_id="O1">
            <title>Lavasept 0.04%</title>
            <description>Reduction in log 10 Colony Forming Units after 60 minutes of treatment</description>
          </group>
          <group group_id="O2">
            <title>Ringer's Solution</title>
            <description>Reduction in log 10 Colony Forming Units after 60 minutes of treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction (log10) in Colony Forming Units</title>
          <description>Comparison of the log10 reduction in CFU after 60 minutes of treatment application.</description>
          <population>ITT population: comprising all wounds having received the study treatment for any duration (n=61).</population>
          <units>log 10 Colony Forming Units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>wounds</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.734" spread="1.00"/>
                    <measurement group_id="O2" value="-0.06" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.006</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local Tolerability: Pruritis Burning</title>
        <description>Local tolerability after 60 minutes of treatment application.</description>
        <time_frame>60 minutes</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction in CFU</title>
        <description>Comparison of the percentage reduction in CFU after 15, 30 and 60 minutes of treatment application</description>
        <time_frame>15 minutes, 30 minutes and 60 minutes</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of the Percentage of Patients With Target Wounds &lt;50 CFU</title>
        <description>Comparison of the percentage of patients with target wounds &lt;50 CFU after 60 minutes of treatment application</description>
        <time_frame>60 minutes</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ringer's Solution</title>
        </group>
        <group group_id="E2">
          <title>Lavasept 0.04%</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs Manager</name_or_title>
      <organization>B. Braun Medical, Centre of Excellence</organization>
      <phone>+41 58 258 55 47</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

